European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
Heart Failure Congress 2009 Presentation
02 Jun 2009

State of the art: prognostication 

Webcasts available

Patrick Jourdain 

Patrick Jourdain
Topics: Heart Failure (HF)
Session number: 1348
Session title: Biomarkers in heart failure today and tomorrow
Authors: Jourdain, Patrick (Pontoise, FR)

webcast View the Webcast

Prognostication is a crucial point in the follow up of heart failure patients. Prognostic is depending of many different aspects of the disease and are mainly based in clinical practice on physician experience and local possibilities (clinical examination, Echocardiography, VO², 6 minute walk test,...)
Natriuretic peptides have proved their usefulness to help clinicians to diagnose heart failure in dyspneic patients. Actually, many studies from litterature support NP use for prognostication in acute and chronic heart failure.
However, NP dosage  must be integrated in a global approach including results from clinical examination and data from the echocardiography. 


Teaching objective of the lecture:

To integrate natriuretic peptides in a routine prognostication  analysis in heart failure patients.

Take home messages:

  • NP are useful prognosticating markers in every day practice
  • NP measurements have to be analysed in relation to clinical examination and other parameters like echo and VO²


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.